India's commercial , financial and creative capital, Mumbai, is all set to witness CPhI India and its co-located events P-MEC/ICSE/BioPh India , largest and most comprehensive pharmaceutical industry event in South Asia .The event is taking place at a time when profound changes are taking place in the international political landscape, which give a new hope for the pharma industry to surge ahead.
Indian generic market, which is moving ahead at a scorching pace as over US$140 billion drugs are going off patent by 2015, will get a booster shot from US President Barack Obama's re-election leading to more generic prescriptions. With health cover being extended to more Americans, the pressure to prescribe and shift to generics will give a further leg up for the industry.
The Indian pharma industry has been consistently growing at a CAGR of more than 15 per cent over the last five years. The healthy growth reflects the inherent strengths of the industry and improving healthcare standards in the country. If this trend continues, the Indian pharma industry is likely to be one of the top 10 global markets by value by 2020, according to a PwC report.
From being a market, almost completely dominated by multinational companies (MNCs) with a high concentration on exports of active pharmaceutical ingredients (API) and generics, India has now proved its prowess in the areas of manufacturing, drug discovery and research. The domestic industry is now moving into the phase of innovation, with a large players as well as smaller niche players, strengthening their research and drug development capabilities and expanding to the developed and regulated international markets.
Thus while the Indian pharmaceutical market is growing twice the world market growth rate, it is also fast evolving into a cradle for new drugs. Being one of the strongest emerging markets in the global pharma industry, India presents great opportunities for all international pharmaceutical companies to explore and benefit from.
As Indian pharma companies are taking giant strides on the international scene, showcasing India’s pharmaceutical might, CPhI India will be revisiting India’s Maximum City from November 21 to 23.
The event will be held at the Bombay Exhibition Centre (BEC), which is one of the largest and prominent exhibition centres in the private sector in India.“Mumbai is the commercial capital of India and is centrally located, providing easy access for our attendees. Additionally, it is one of the few cities that feature a venue with the proper infrastructure and accommodations for the large size of CPhI and P-MEC India. Specifically, the Bombay Convention Centre is ideally situated close to hotels and entertainment, in addition to being along the Western Express Highway in Goregaon, around 10 minutes from the airport and close to the heart of the city by foot or train", says Haf Cennydd , Global Brand Director at UBM Live, organizer of CPhI India event.
This mega trade fair is an ideal platform for all the leading players of the related industries to showcase the latest and upcoming trends of the Indian pharmaceutical market. The event would bring together world’s leading pharmaceutical trade brands with one of the world’s most fertile and fast-moving pharma markets.
Says Haf Cennydd, “Our main theme stems from the ethos of the CPhI brand as a whole, which is to drive growth and innovation in the pharma industry across the globe. CPhI and P-MEC India do this by providing a leading global event format that covers every step of the supply chain from drug discovery to finished dosage. We also offer a unique platform for the most active buyers to identify business opportunities and meet with potential partners, while also having access to networking and educational features that are unmatched. All of it leads into our desire to see the industry move forward for the greater good".
From its inception in 2006, CPhI India has seen several alliances and partnerships forming, reshaping and renewing under its roof. Besides, it has also offered a plethora of networking opportunities to the participants. The combined exhibitions are the largest pharma services in India and South Asia.
Each year, the exhibition has grown larger with exhibitors and visitors doing significant level of business. This annually held event is known for gathering the domestic and foreign drug makers, contract service providers and pharma machinery players under one roof and giving them a chance to put their heads together to chart out the future growth plans. The event within a short period of time has become South Asia's leading pharma meeting place.
This year too, the convention would provide a vital podium for building new business relationships and networking, especially for international companies which wish to enter the Indian market. CPhI India brings pharma professionals from all over the world to India and facilitates serious business deals. The participants can take this opportunity to showcase their products and services and can also enhance their brand image.
CPhI India will attract a great number of high profile visitors including industry professionals from general management,marketing & sales, purchasing, production, quality control, engineering & R& D, decision makers from the entire chemical & pharmaceutical industry searching for new products, services & deals. CPhI India thus brings pharma professionals from all over the world to Mumbai and facilitate initiating and closing business deals.
Exhibitors from China, France, Germany, India, Israel, Italy, Japan, Korea, Switzerland, the UAE, UK and USA to name a few, will present over 40 categories of pharmaceutical ingredients and allied products. Focussed on pharmaceutical ingredients, machinery, equipment, research, outsourcing and bio-solutions for pharma, CPhI India brings together high-quality prospects that are actively looking for these products and services.
The exhibitor profile includes active pharmaceutical ingredients, intermediates, excipients and natural extracts to experts in custom manufacturing and marketing service, analytical services, antibiotics, antibodies & antioxidants, biotechnology, chemicals & intermediates, cytokines & solvents, excipients & drug formulation, natural extracts and so on.
Running parallel to the exhibition, Technical Seminars will be presented by eminent experts from the industry will cover trend topics within the pharma industry. Sessions running within a 45-minute slot will enable the attendants to know all about their latest products, innovations, services.
As every year, Pharmexcil (Pharmaceuticals Export Promotion Council of India) will be organising a Pharmexcil Pavilion at CPhI India to boost business, providing unique opportunity to participants to hold a stall and participate. Around 108 stalls shall be part of this pavilion.
The French Trade Commission will have a French Pavilion bringing together six companies specialised in products or services for the pharmaceutical industry.
French companies can propose active ingredients, innovative technologies, packaging, services like toxicology studies, laboratory and process equipment, technology for cold chain, imaging and tracking systems, clean rooms etc. to the Indian pharmaceutical industry.
This year the organizers are hosting the CPhi India Pharma Awards for the first time. The pharmaceutical industry in India is at a critical juncture when there is a lot of moderation required by the industry players. Globally, CPhI is an industry with continuous innovation and still with an ample scope to improve various facets of operations. CPhI India Pharma Awards look at the efforts being made by the industry players as well as motivating others to continue the innovative works.
The process advisors of the awards are Ernst & Young. Organised by UBM, CPhI India Awards is supported by Pharmexcil and Brand India Pharma. The evaluation of the awards are being done by an independent panel of senior industry professionals. The award distribution event will be held on November 21.
CPhI India Pharma Awards 2012 will recognize and reward selected path-breaking initiatives undertaken by the Indian pharma industry in key areas of quality, product design, cost management, packaging and environmental health & safety. These initiatives will pave way for stable growth, provide universal health benefits as well as social and environmental safety, resulting ultimately in enhancing the global image of the Indian pharmaceutical industry.
Along with the pharmaceutical industry , Indian machinery and equipment market is also growing rapidly. The machinery and equipment market is growing at an average of 15-20 per cent per year.
Decision-makers from all over the world are increasingly looking at India for sourcing pharmaceutical machinery and equipment.
As a result of this, P-MEC has seen increasing levels of interest over the last few years. P-MEC India will give the exhibitors valuable insights into the future of pharma equipment and machinery, highlighting the latest knowledge and trends in the market. It provides unmatched opportunity for exhibitors to meet new and existing clients, to find and approach new markets and to stay abreast of new developments in pharma manufacturing.
Held alongside P-MEC India, ICSE attracts exhibitors who are keen to capitalise on extending their outsourcing business in India. Global pharmaceutical companies are also looking to India as an international hub for contract research and manufacturing (CRAMS) even as pharmaceutical outsourcing in India is on the increase.
ICSE connects the pharmaceutical community with outsourcing solution providers, offering a forum for business development, networking and education. Besides contract manufacturing and contract research, other main services provided are packaging, clinical trials, laboratory services, drug discovery and marketing services. Dedicated to the contract services part of the pharmaceutical manufacturing process, ICSE India, will emphasise on the fast-growing outsourcing and contract services sector.
At the same time BioPh will offer a natural business platform to the world of pharma, focussing on biopharmaceutical development and services, both face to face and online.
The mix of exhibition and seminars at BioPh will offer a great platform for all companies and organisations dealing with the R&D of new treatment methods made through biotechnological processes or which are derived from or use live organisms to benefit from.
The last year's event was also a big draw. "Last year featured over 27,000 attendees including participation from key industry companies such as BASF India, Lupin, Piramal Healthcare, Merck, SGS Life Science and Aurobindo Pharma. Our feedback from attendees and exhibitors alike were very positive, indicating that CPhI and P-MEC provide an efficient and effective platform for the most active buyers to identify business opportunities and meet with potential partners to move the industry forward" says Haf Cennydd commenting on the CPhI India 2011 event.